The issue is the validity of the NWBO Phase 3 trial. As, what has been presented adds significant questions about the trial validity, a presentation by Dr. Liau on the trial does not assuage those questions.
NICE won't cover DCVax-L until MHRA actually approves it for commercial use in the UK. NICE may consider covering it for compassionate use coverage.
Spoofing lawsuit has nothing to do with the legitimacy of the clinical trial that will determine regulator approval likelihood and the ability of NWBO to survive.
So thanks, but no thanks. Read/listened to them all, the same issues are still there.
Market Data 
Markets 
AI
